Prophylactic Tocilizumab in Participants with Relapsed/Refractory Multiple Myeloma Treated with Linvoseltamab in the Outpatient Setting

The purpose of this study is to look at whether giving tocilizumab before linvoseltamab can help reduce the risk or severity of cytokine release syndrome, a possible side effect of treatment, among adults with relapsed or refractory multiple myeloma.

• Adults 18+ years of age
• Confirmed relapsed/refractory multiple myeloma
• Must have had disease progression after at least 4 prior lines of therapy, including a proteasome inhibitor, an IMiD, and an anti-CD38 antibody
• Have an ECOG performance status of 0–2
• Must also have confirmed progressive disease after their most recent therapy
• No plasma cell leukemia, symptomatic amyloidosis, Waldenström macroglobulinemia, POEMS syndrome, known myeloma involvement of the brain/meninges, or certain neurologic conditions

• Receiving prophylactic tocilizumab before outpatient treatment with linvoseltamab
• Attending regular clinic visits
• Completing lab tests, disease assessments, and safety monitoring for side effects such as cytokine release syndrome